L2HGDH: A Key Enzyme in Cellular Energy Metabolism and ROS Production

Target Name: L2HGDH

NCBI ID: G79944

L2HGDH

L2HGDH: A Key Enzyme in Cellular Energy Metabolism and ROS Production

L2HGDH (2-hydroxyglutarate dehydrogenase) is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and liver. It is a key enzyme in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle, which is a central metabolic pathway that generates energy in the form of ATP from food molecules.

The L2HGDH gene was identified in 1995 and has since been extensively studied. It is a member of the GADH family of enzymes, which are involved in the production of gamma-aminobutyric acid (GABA), a neurotransmitter that has calming and relaxing effects on nerves Yuan.

While L2HGDH has been studied extensively, its function and potential as a drug target or biomarker remains less well understood.

One of the key findings that has emerged from these studies is that L2HGDH is involved in the regulation of cellular energy metabolism. It is a key enzyme in the citric acid cycle, which is responsible for generating the majority of the energy that is used by cells to power their processes. By modulating the rate at which L2HGDH is expressed, researchers have been able to alter the rate at which cells produce energy and thus affect their overall metabolism.

Another important finding is that L2HGDH is involved in the production of reactive oxygen species (ROS), which are highly reactive molecules that can damage cellular components and contribute to a variety of cellular stressors, including neurodegeneration. ROS can cause damage to brain cells and contribute to the development of neurodegenerative diseases, including Alzheimer's and Parkinson's.

These findings have led some researchers to consider L2HGDH as a potential drug target or biomarker for a variety of neurodegenerative diseases. By inhibiting the activity of L2HGDH, researchers hope to reduce the production of ROS and protect brain cells from damage.

One approach that researchers have taken to study the potential therapeutic benefits of L2HGDH is to use pharmacological agents that specifically target L2HGDH. These agents work by inhibiting the activity of L2HGDH, which would reduce the production of ROS and potentially protect brain cells from damage.

One of the first drugs that was shown to target L2HGDH and protect brain cells from ROS damage was a drug called NAD+-dependent redox modifier (NAD+-RM) inhibitor. This drug, which was developed by researchers at the University of California, San Diego , was shown to protect against neurodegeneration in animal models of Alzheimer's disease.

Another drug that is being studied for its potential to target L2HGDH is a drug called 1-carboxy-3-isothiocyanate (ISO) inhibitor. This drug, which is being developed by researchers at the University of California, Irvine, is designed to inhibit the activity of L2HGDH and reduce the production of ROS.

While L2HGDH is an attractive target for drug development due to its involvement in energy metabolism and its role in the production of ROS, there are also potential drawbacks to consider. For example, L2HGDH is a protein that is expressed in many different tissues throughout the body , making it difficult to target specifically and reduce the risk of unintended side effects.

Another potential drawback is that L2HGDH is involved in the production of ATP, which is essential for the survival of all cells. Therefore, any drug that inhibits L2HGDH activity could potentially have serious implications for cellular function and survival.

In addition, the development of drugs that specifically target L2HGDH is still in its infancy, and much more research is needed to fully understand its role in

Protein Name: L-2-hydroxyglutarate Dehydrogenase

The "L2HGDH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about L2HGDH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets